Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITCA 650 versus empagliflozin or glimepiride added to metformin in adults with type 2 diabetes
NL-OMON45372Phase 3Not yet recruiting
- Sponsor
- Intarcia Therapeutics
- Start
- Aug 2017
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing ITCA 650 add-on to metformin, Empagliflozin add-on to metformin and Glimepiride add-on to metformin (3 arms). Primary endpoints: Change from baseline in HbA1c at Week 65 and Change from baseline in weight at Week 65. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
ITCA 650empagliflozinglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON45372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45372.